Search for content, post, videos

AstraZeneca’s PROVENT trial met primary endpoint

Mene Pangalos
AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77%, compared to placebo. The Phase III trial accrued 25 cases of symptomatic COVID-19 at the primary analysis. There were no cases of severe COVID-19 or COVID-19-related deaths in
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.